Adjuvant Therapy for Breast Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Adjuvant Therapy for Breast Cancer PDF full book. Access full book title Adjuvant Therapy for Breast Cancer by Monica Castiglione. Download full books in PDF and EPUB format.
Author: Monica Castiglione
Publisher: Springer Science & Business Media
ISBN: 0387751157
Category : Medical
Languages : en
Pages : 483
Get Book
Book Description
Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
Author: Monica Castiglione
Publisher: Springer Science & Business Media
ISBN: 0387751157
Category : Medical
Languages : en
Pages : 483
Get Book
Book Description
Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
Author: Monica Castiglione
Publisher: Springer
ISBN: 9781461417163
Category : Medical
Languages : en
Pages : 0
Get Book
Book Description
Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
Author: Monica Castiglione
Publisher: Springer
ISBN: 9780387751146
Category : Medical
Languages : en
Pages : 490
Get Book
Book Description
Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
Author: I. Craig Henderson
Publisher: Springer Science & Business Media
ISBN: 1461534968
Category : Medical
Languages : en
Pages : 462
Get Book
Book Description
The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer. Many of the tumors that we have been most successful in curing with chemotherapy and other newer forms of treatment are relatively uncommon. In contrast, breast cancer continues to be the single most common malignancy among women in the western world, is increasingly a cause of death throughout Asia and Third-World countries, and remains one of the most substantial causes of cancer mortality world wide. The use of mammography as a means of early detection has been shown to reduce breast cancer mortality by 25-35% among those popu lations in which it is utilized. The use of adjuvant systemic treatment in appropriate patients provides a similar (and additional) reduction in breast cancer mortality. Few subjects have been so systematically studied in the history of medicine, and it seems fair to conclude that the value to adjuvant systemic therapy in prolonging the lives of women with breast cancer is more firmly supported by empirical evidence than even the more conventional or primary treatments using various combinations ofsurgery and radiotherapy.
Author: Hans-Jörg Senn
Publisher: Springer Science & Business Media
ISBN: 364245769X
Category : Medical
Languages : en
Pages : 505
Get Book
Book Description
This RRCR-conference-volume marks "number six" in a 20-year evolution of international conferences on the adjuvant therapy of primary breast cancer. Starting in 1978, a handful of some 80 en thusiastic breast cancer surgeons and oncologists, met in a se cluded mountain resort near st. Gallen in Eastern Switzerland, to exchange their early data of some pioneer trials on adjuvant sys temic therapy of early breast cancer, and to correlate their future research efforts to overcome the frustrating prognostic stagna tion of this dominant neoplastic disease in Western females dur ing the past decades. Repeated every 3-4 years, these St. Gallen International Conferences on Adjuvant Therapy of Primary Breast Cancer have continuously grown in numbers of partici pants and in normative, therapeutic influence by being published in major oncology journals [1-3], the last (6th) conference hav ing taken place from February 25-28, 1998 with more than 1800 attendees from over 50 countries worldwide. What is the fascination of adjuvant therapy in primary (early) breast cancer, and what has changed,during the last 3 years since March 1995, to justify another international gathering of this size, and of the world's leading experts in the field? There is no question, that providing even more effective care and designing appropriate recommendations for the multitudes of patients with so-called early breast cancer or at high risk of developing the disease, remain highly important public health goals.
Author: Hans-Jörg Senn
Publisher: Springer Science & Business Media
ISBN: 3642792782
Category : Medical
Languages : en
Pages : 337
Get Book
Book Description
We often hear physicians, health care professionals, poli ticians, and patient advocates that "nothing has happened in the treatment of breast cancer," since patients with breast cancer, the most frequent neoplastic condition in women in industrialized countries, are continuing to suffer relapse and succumb to this dreadful disease! This negativistic attitude does not seem to be justified, but, why is the transmission of clinical trial results into general practice, and with it progress, such a slow process? After many decades of frustrating stagnation of long-term survival expectations, in all stages of early, oper/lble breast cancer treated only by surgery and locoregional radio therapy, adjuvant systemic therapy (chemo- as well as endocrine treatments) clearly showed to significantly benefit in terms of disease-free and overall survival. This evolution has been extensively expounded on by the Worldwide Oxford Overview and the Expert Consensus Panel at the fourth International Conference 'on Adjuvant Therapy of Primary Breast Cancer in St. Gallen (Early Breast Cancer Trialists' Collaborative Group 1992; Glick et al. 1992). What has happened since then? During the past 3-5 years, several new concepts and treatment strategies have emerged and have been studied in various major breast cancer groups and treatment centers worldwide. Some of these can already be considered to assist in the primary treatment of operable breast cancer today, while others are . still undergoing clini,cal trials for better definition of their practical usefulness.
Author:
Publisher:
ISBN:
Category : Breast
Languages : en
Pages : 16
Get Book
Book Description
Author: Kathy Miller
Publisher: IOS Press
ISBN: 9781586035006
Category : Medical
Languages : en
Pages : 78
Get Book
Book Description
The efficacy of adjuvant chemotherapy was first demonstrated in the early 1970's. Prolonged follow-up of these trials confirms the lasting improvement in overall survival with the administration of adjuvant chemotherapy. The early meta-analysis offers the practicing physician a good sense of the broad trends in adjuvant therapy (both chemotherapy and hormonal therapy), but falls short during periods of rapid changes in available agents or approaches. This volume deals with different views on the early overview. One view highlights therapeutic advances that have not yet been incorporated. Another view places the overview in context, contrasting the consensus recommendations with actual delivery of therapy in the community. While the overview provides meaningful guidelines for the patient with an 'average risk' early breast cancer, oncologists routinely struggle with patients at either end of the risk spectrum. In this volume, the use of neoadjuvant chemotherapy is looked at. This was initially reserved for patients with locally advanced or inflammatory disease. Adjuvant treatment decisions are based largely on the results of randomized clinical trials. necessarily unrepresentative of the general population of breast cancer patients. Another point is that in real life, clinical therapy frequently requires a series of negotiations between patient and physician, especially with the explosion of the Internet, which makes it easier for patients to find (mis)information.
Author: Hans-Jörg Senn
Publisher: Springer Science & Business Media
ISBN: 3642833373
Category : Medical
Languages : en
Pages : 440
Get Book
Book Description
The ultimate "consumer" of the data presented at conferences on the primary treatment of operable breast cancer is the patient, and when, as in this disease, the benefits of therapy are relatively mod est, the availability and interpretation of the data from trials be comes an issue of primary importance. The effects of present treat ment are in fact such that more patients relapse despite therapy than are estimated to benefit from it. It is, therefore, extremely dif ficult for the physician to recommend unequivocally one particular adjuvant treatment modality for the vast population of women with breast cancer. The interpretation of results from clinical research-oriented pro grams is constantly applied, however, in the treatment of breast cancer patients outside of clinical trials. From presented or publish ed data, many physicians extrapolate indications for the use of a given treatment regimen for their patients, perceiving it as the "best available therapy. " It is essential that the "best available therapy" be selected individually for each patient. However, considering the modest effect of treatment upon outcome, it is imperative that those who provide the data - those who are involved in both pa tient care and clinical research - make it known that the best cur rent treatment for the population of breast cancer patients is avail able within the framework of clinical trials. In this way not only present-day patients but also future ones will derive the greatest benefit.
Author: Joseph Ragaz
Publisher: Springer Science & Business Media
ISBN: 3642826717
Category : Medical
Languages : en
Pages : 172
Get Book
Book Description
Despite recent advances in adjuvant therapies of cancer, the regi mens of postoperative adjuvant chemotherapy treatment which are presently available fail to cure the majority of cancer patients. Pre operative (neoadjuvant) chemotherapy represents a new approach in drug scheduling, based on sound theoretical, pharmacokinetic, and experimental principles. The preoperative timing of chemotherapy before definitive sur gery is not a minor change in the therapy of cancer. To be successful, large numbers of practitioners and their patients must participate. Substantial alterations of many aspects of the present management of cancer will have to follow. Therefore, before such therapy can be fully and routinely implemented, results of the novel treatment and its rationale have to be carefully evaluated. In preoperative treatment, other features will likely gain impor tance. For the first time, clinicians have a chance to follow the in vivo response of the tumor exposed to preoperative chemotherapy. The subsequent histological assessment of the tumor sample may likely become an important prognostic guide, permitting more re fined individual approaches to the planning of postoperative adju vant treatment. The value of such a treatment strategy can already be appreciated in the clinical setting, as seen from the therapy of osteosarcoma. Furthermore, preoperative chemotherapy might render previously inoperable tumors operable and hence resectable with a curative intention. The preoperative reduction of tumor bulk may also effectively decrease the need for more radical operations, permitting a more uniform adoption of conservative surgery.
